Transplantation and Cellular Therapy · 2021 · 15 citations · 32 references
MedicineImmunologyCell TherapyStem Cell TransplantationTransplant ImmunologyAllogeneic Stem Cell TransplantationGraft-versus-host DiseaseHematopoietic Stem Cell TransplantationPediatric TransplantationTransplant ComplicationsTransplant OutcomesHaploidentical Transplant ConditioningHematopoietic Stem Cell Transplant ConditioningNonmyeloablative ConditioningPeripheral Blood Stem CellsPost-transplant CyclophosphamideSibling Donor MatchingTransplantationTransplantation Outcome Assessment
Haploidentical stem cell transplantation (SCT) using post-transplantation cyclophosphamide for graft-versus-host disease (GVHD) prophylaxis is a reasonable therapeutic option for patients who do not have a matched sibling donor. Between 2010 and June 2020, 257 patients underwent 269 Haploidentical transplantations, including 122 children. Indications included both malignant (56.8%) and non-malignant (43.2%) diseases. Conditioning regimens included both myeloablative (57.6%) and nonmyeloablative regimens (42.4%). Peripheral blood stem cells were the predominant graft source (96.2%). Based on the disease risk index, patients were classified into early-, intermediate-, and late-stage disease. Engraftment was seen in 205 patients (76.2%) whereas 39 (14.4%) died before engraftment and 23 (8.6%) had primary graft failure. The cumulative incidence of grade II-IV acute GVHD was 47.8% with a 23.9% incidence of grade III-IV acute GVHD. Chronic GVHD was seen in 41.9% with a 15.4% incidence of extensive chronic GVHD. More than 90% had at least 1 documented infection with a 44% incidence of bacterial, 71% viral, and 38% fungal infection. The 2-year overall survival is 40.5% ± 3.2% with a higher survival among children (48.2% ± 3.4%) compared to adults (34.2% ± 4.1%). Survival was poor with late-stage disease (23.6% ± 4.3%) compared to early- (62.5% ± 7.5%) and intermediate-stage (50.3% ± 4.3%). Factors adversely affecting survival included older age of patient (P = .007), late disease status (P = .000), nonmyeloablative conditioning regimen (P = .003), bone marrow as graft source (P = .006), presence of acute GVHD (P = .069), primary graft failure (P = .000), and presence of a documented bacterial (P = .000) and fungal infection (P = .000). On multivariate analysis, older age (P = .027), presence of acute GVHD (P = .033), documented bacterial infection (P = .000), documented fungal infection (P = .000) and primary graft failure (P = .012) continued to remain significant. Haploidentical SCT offers a reasonable chance of cure for patients with both malignant and nonmalignant hematological diseases. Strategies to reduce aGVHD and infection related mortality needs to be explored further. © 20XX American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
32
Leo Luznik, Paul V. O’Donnell, Heather J. Symons et al. · Biology of Blood and Marrow Transplantation · 2008 · 1.9K citations · Full text
Medicine, Hematology, Oncology +16
Anna Maria Raiola, Alida Dominietto, Anna Ghiso et al. · Biology of Blood and Marrow Transplantation · 2012 · 374 citations · Full text
Medicine, Hematology, Immunology +16